Peter Reynolds

The life and times of Peter Reynolds

Posts Tagged ‘Parkinson’s

Let’s Get The Dealers Off The Streets!

leave a comment »

 

Cannabis Is Not A Controlled Drug

Present policy abandons control to organised crime and street dealers.

If cannabis were properly controlled, it would be taken out of the hands of criminals. Growing, importing, distributing and retailing would become legitimate businesses, subject to proper control and regulation.

What Proper Control Would Mean

  • Regulated sales: licensed retailers, labelling of THC/CBD ratio, other ingredients, weight
  • Quality control: elimination of pesticide and fertiliser residues, bulking agents, impurities
  • Regulated commercial production, reasonable limits on domestic cultivation
  • Protecting the vulnerable: age limit, ID check, harm reduction information

We Need CLEAR Common Sense About Cannabis.

advan-poster

Download PDF (10MB)

A Safer Britain

  • Less crime of all types
  • Police can focus on violent and harmful crime
  • Lower alcohol consumption
  • Fewer road accidents and injuries/fatalities
  • Fewer children using cannabis
  • Quality controlled cannabis with no harmful adulterants
  • Fewer fires from hidden cannabis farms

A Healthier Britain

  • Lower alcohol consumption
  • Less use of dangerous/harmful drugs
  • Medicinal use: Alzheimer’s, arthritis, cancer, chronic. pain, dementia, diabetes, epilepsy, glaucoma, MS,. Parkinson’s, stroke therapy.
  • Preventative therapy against auto immune and neurodegenerative diseases
  • More funding for healthcare

Taxing The UK Cannabis Market

CLEAR’s policies are based on independent, expert research carried out by the Independent Drug Monitoring Unit in 2011.

Download Here (PDF)

How To Regulate Cannabis In Britain

CLEAR’s detailed proposals for cannabis regulation so as to minimise all health and social harms of cannabis, protect the vulnerable and allow access to medicinal cannabis

Download Here (PDF)

References:

The Effect of Medical Marijuana Laws on Crime, March 2014
Read here
How Smoking Marijuana Might Be The Best Way To Prevent Alzheimer’s Disease, January 2014
Read Here
Few Problems With Cannabis for California, October 2013
Read Here
The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance, July 2013
Read Here
Medical Marijuana Laws, Traffic Fatalities, and Alcohol Consumption, May 2013
Read Here
Why Medical Marijuana Laws Reduce Traffic Deaths, December 2011
Read Here
What can we learn from the Dutch cannabis coffeeshop system? September 2011
Read Here
Study: Legal Medical Marijuana Doesn’t Encourage Kids to Smoke More Pot, November 2011
Read Here

.

‘Taxing the UK Cannabis Market’, 2011
Read Here
A summary of the health harms of drugs. NHS, 2011.
Read Here
Emerging Clinical Applications For Cannabis & Cannabinoids. A Review of the Recent Scientific Literature 2000 – 2011, NORML, 2011.
Read Here
Bringing cannabis back into the medicine cabinet, Prof. Les Iversen, 2010.
Video here
Dutch among lowest cannabis users in Europe, November 2009
Read More
Adulterants & Cutting Agents Found in Cannabis Resin, 2009
Read Here
Key Marijuana Compound Beats Current Alzheimer’s Drugs, August 2006
Read Here
US Patent 6630507, Cannabinoids as Antioxidants and Neuroprotectants, 2001
Read Here

 

 

Advertisements

Peter Reynolds’ Letter Published In The Daily Telegraph, 18th April 2014

leave a comment »

British Medicinal Cannabis Register

with 16 comments

In California there are more than 500,000 medical marijuana card holders.  How many people use cannabis as medicine in Britain?

The British Medicinal Cannabis Register aims to find out and provide a database of facts and evidence for doctors, scientists, researchers, campaigners, government and anyone with a bona fide interest.   Users register via the BMCR website, providing details of their method of use and the conditions treated.  While patient confidentiality is guaranteed and records held on the database will have the same legal status as any other medical record, users do not have to provide their full address.   They can register with the first part of their postcode and a verifiable email address.

Of course, according to the British government, “cannabis is dangerous and has no medicinal benefits”.  However, Sativex, a cannabis tincture, has been approved by the MHRA as a treatment for MS spasticity.  Sativex is pharmacologically identical to cannabis.  It is cannabis – with the addition of ethanol and a little peppermint oil. (A tincture is an alcoholic extract.)

There is no more common sense in US federal law where cannabis is a schedule 1 drug with “no medicinal uses”, yet the US government has held a patent  (no. 6630507) since 2003 for “cannabinoids as antioxidants and neuroprotectants, for example, in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

If you can make any sense of either the British or US governments’ position then please educate me?   I think they are irrational and cruel.  They actively deny people in pain and suffering the relief they need which is comprehensively proven both by science and experience.  On both sides of the Atlantic this amounts to nothing less than an evil injustice and oppression of vulnerable people.

Thank God and the US constitution that in America 14 states have introduced a regulated system of medical marijuana.  Two-thirds of Europe permits medicinal cannabis and Israel has just introduced a major programme including new growing facilities and dispensaries.  In Britain there is no such compassion and the Home Office ducks and dives and manipulates and dissembles to evade EU law that would permit cannabis as medicine.  In the UK there is appalling wickedness and cruelty perpetrated on the back of political cowardice.

Baroness Meacher

The BMCR was launched this week and received an immediate boost with the announcement of Baroness Molly Meacher, Paul Flynn MP,  Matthew Atha and Dr Michael Vandenburg as members of its governing council.  Baroness Meacher has a distinguished career in health and social care.  Paul Flynn has long campaigned for drug law reform.  Matthew Atha is the director of the Independent Drug Monitoring Unit and Dr Michael Vandenburg is the pre-eminent expert witness in the courts on pharmaceuticals and drugs.

Whether the BMCR succeeds in its aims depends entirely on whether those who use cannabis as medicine have the courage to register.  Only then will sufficent evidence be available to embarrass the government into essential and overdue reform.  The danger is that those who find relief  will prefer to keep quiet and say nothing.  No one could blame them if they do.

It is time for all those concerned to grasp this nettle and make a stand. Are we seriously going to continue to imprison sick and disabled people for using a medicine that is proven to be effective and far less costly, dangerous and harmful than pharmaceutical alternatives?

I urge all those concerned to register at the BMCR website: www.bmcr.org.uk.